Post-recurrence survival in patients with cervical cancer

J 2022

Post-recurrence survival in patients with cervical cancer

CIBULA, David, Lukáš DOSTÁLEK, Jiří JARKOVSKÝ, Constantijne H MOM, Aldo LOPEZ et. al.

Basic information

Original name

Post-recurrence survival in patients with cervical cancer

Authors

CIBULA, David (203 Czech Republic, guarantor), Lukáš DOSTÁLEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Constantijne H MOM, Aldo LOPEZ, Henrik FALCONER, Giovanni SCAMBIA, Ali AYHAN, Sarah H KIM, David Isla ORTIZ, Jaroslav KLAT, Andreas OBERMAIR, Giampaolo Di MARTINO, Rene PAREJA, Ranjit MANCHANDA, Jan KOSŤUN, Ricardo dos REIS, Mehmet Mutlu MEYDANLI, Diego ODETTO, Rene LAKY, Ignacio ZAPARDIEL, Vít WEINBERGER (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Martina BORČINOVÁ (203 Czech Republic), Fernando CARDENAS, Emelie WALLIN, Luigi Pedone ANCHORA, Huseyin AKILLI, Nadeem R ABU-RUSTUM, Salim Abraham BARQUET-MUÑOZ, Veronika JAVŮRKOVÁ (203 Czech Republic), Daniela FISCHEROVÁ (203 Czech Republic) and Luc R C W van LONKHUIJZEN

Edition

Gynecologic Oncology, San Diego, Elsevier, 2022, 0090-8258

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.700

RIV identification code

RIV/00216224:14110/22:00125157

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.ygyno.2021.12.018

UT WoS

000789325700017

Keywords in English

Early-stage cervical cancer; Recurrence; Post-recurrence disease-specific survival; Prognosis; Multivariable model; Risk profile

Abstract

V originále

Background Up to 26% of patients with early-stage cervical cancer experience relapse after primary surgery. However, little is known about which factors influence prognosis following disease recurrence. Therefore, our aims were to determine post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors for PR-DSS. Methods Data from 528 patients with early-stage cervical cancer who relapsed after primary surgery performed between 2007 and 2016 were obtained from the SCANN study (Surveillance in Cervical CANcer). Factors related to the primary disease and recurrence were combined in a multivariable Cox proportional hazards model to predict PR-DSS. Results The 5-year PR-DSS was 39.1% (95% confidence interval [CI] 22.7%–44.5%), median disease-free interval between primary surgery and recurrence (DFI1) was 1.5 years, and median survival after recurrence was 2.5 years. Six significant variables were identified in the multivariable analysis and were used to construct the prognostic model. Two were related to primary treatment (largest tumour size and lymphovascular space invasion) and four to recurrence (DFI1, age at recurrence, presence of symptoms, and recurrence type). The C-statistic after 10-fold cross-validation of prognostic model reached 0.701 (95% CI 0.675–0.727). Three risk-groups with significantly differing prognoses were identified, with 5-year PR-DSS rates of 81.8%, 44.6%, and 12.7%. Conclusions We developed the robust model of PR-DSS to stratify patients with relapsed cervical cancer according to risk profiles using six routinely recorded prognostic markers. The model can be utilised in clinical practice to aid decision-making on the strategy of recurrence management, and to better inform the patients.

Citovat

CIBULA, David, Lukáš DOSTÁLEK, Jiří JARKOVSKÝ, Constantijne H MOM, Aldo LOPEZ, Henrik FALCONER, Giovanni SCAMBIA, Ali AYHAN, Sarah H KIM, David Isla ORTIZ, Jaroslav KLAT, Andreas OBERMAIR, Giampaolo Di MARTINO, Rene PAREJA, Ranjit MANCHANDA, Jan KOSŤUN, Ricardo dos REIS, Mehmet Mutlu MEYDANLI, Diego ODETTO, Rene LAKY, Ignacio ZAPARDIEL, Vít WEINBERGER, Klára BENEŠOVÁ, Martina BORČINOVÁ, Fernando CARDENAS, Emelie WALLIN, Luigi Pedone ANCHORA, Huseyin AKILLI, Nadeem R ABU-RUSTUM, Salim Abraham BARQUET-MUÑOZ, Veronika JAVŮRKOVÁ, Daniela FISCHEROVÁ and Luc R C W van LONKHUIJZEN. Post-recurrence survival in patients with cervical cancer. Gynecologic Oncology. San Diego: Elsevier, 2022, vol. 164, No 2, p. 362-369. ISSN 0090-8258. Available from: https://dx.doi.org/10.1016/j.ygyno.2021.12.018.

@article{1819487,
   author = {Cibula, David and Dostálek, Lukáš and Jarkovský, Jiří and Mom, Constantijne H and Lopez, Aldo and Falconer, Henrik and Scambia, Giovanni and Ayhan, Ali and Kim, Sarah H and Ortiz, David Isla and Klat, Jaroslav and Obermair, Andreas and Martino, Giampaolo Di and Pareja, Rene and Manchanda, Ranjit and Kosťun, Jan and Reis, Ricardo dos and Meydanli, Mehmet Mutlu and Odetto, Diego and Laky, Rene and Zapardiel, Ignacio and Weinberger, Vít and Benešová, Klára and Borčinová, Martina and Cardenas, Fernando and Wallin, Emelie and Anchora, Luigi Pedone and Akilli, Huseyin and AbuandRustum, Nadeem R and BarquetandMuñoz, Salim Abraham and Javůrková, Veronika and Fischerová, Daniela and Lonkhuijzen, Luc R C W van},
   article_location = {San Diego},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.ygyno.2021.12.018},
   keywords = {Early-stage cervical cancer; Recurrence; Post-recurrence disease-specific survival; Prognosis; Multivariable model; Risk profile},
   language = {eng},
   issn = {0090-8258},
   journal = {Gynecologic Oncology},
   title = {Post-recurrence survival in patients with cervical cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S0090825821016759?via%3Dihub},
   volume = {164},
   year = {2022}
}

TY  - JOUR
ID  - 1819487
AU  - Cibula, David - Dostálek, Lukáš - Jarkovský, Jiří - Mom, Constantijne H - Lopez, Aldo - Falconer, Henrik - Scambia, Giovanni - Ayhan, Ali - Kim, Sarah H - Ortiz, David Isla - Klat, Jaroslav - Obermair, Andreas - Martino, Giampaolo Di - Pareja, Rene - Manchanda, Ranjit - Kosťun, Jan - Reis, Ricardo dos - Meydanli, Mehmet Mutlu - Odetto, Diego - Laky, Rene - Zapardiel, Ignacio - Weinberger, Vít - Benešová, Klára - Borčinová, Martina - Cardenas, Fernando - Wallin, Emelie - Anchora, Luigi Pedone - Akilli, Huseyin - Abu-Rustum, Nadeem R - Barquet-Muñoz, Salim Abraham - Javůrková, Veronika - Fischerová, Daniela - Lonkhuijzen, Luc R C W van
PY  - 2022
TI  - Post-recurrence survival in patients with cervical cancer
JF  - Gynecologic Oncology
VL  - 164
IS  - 2
SP  - 362-369
EP  - 362-369
PB  - Elsevier
SN  - 00908258
KW  - Early-stage cervical cancer
KW  - Recurrence
KW  - Post-recurrence disease-specific survival
KW  - Prognosis
KW  - Multivariable model
KW  - Risk profile
UR  - https://www.sciencedirect.com/science/article/pii/S0090825821016759?via%3Dihub
N2  - Background Up to 26% of patients with early-stage cervical cancer experience relapse after primary surgery. However, little is known about which factors influence prognosis following disease recurrence. Therefore, our aims were to determine post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors for PR-DSS. Methods Data from 528 patients with early-stage cervical cancer who relapsed after primary surgery performed between 2007 and 2016 were obtained from the SCANN study (Surveillance in Cervical CANcer). Factors related to the primary disease and recurrence were combined in a multivariable Cox proportional hazards model to predict PR-DSS. Results The 5-year PR-DSS was 39.1% (95% confidence interval [CI] 22.7%–44.5%), median disease-free interval between primary surgery and recurrence (DFI1) was 1.5 years, and median survival after recurrence was 2.5 years. Six significant variables were identified in the multivariable analysis and were used to construct the prognostic model. Two were related to primary treatment (largest tumour size and lymphovascular space invasion) and four to recurrence (DFI1, age at recurrence, presence of symptoms, and recurrence type). The C-statistic after 10-fold cross-validation of prognostic model reached 0.701 (95% CI 0.675–0.727). Three risk-groups with significantly differing prognoses were identified, with 5-year PR-DSS rates of 81.8%, 44.6%, and 12.7%. Conclusions We developed the robust model of PR-DSS to stratify patients with relapsed cervical cancer according to risk profiles using six routinely recorded prognostic markers. The model can be utilised in clinical practice to aid decision-making on the strategy of recurrence management, and to better inform the patients.
ER  -

CIBULA, David, Lukáš DOSTÁLEK, Jiří JARKOVSKÝ, Constantijne H MOM, Aldo LOPEZ, Henrik FALCONER, Giovanni SCAMBIA, Ali AYHAN, Sarah H KIM, David Isla ORTIZ, Jaroslav KLAT, Andreas OBERMAIR, Giampaolo Di MARTINO, Rene PAREJA, Ranjit MANCHANDA, Jan KOSŤUN, Ricardo dos REIS, Mehmet Mutlu MEYDANLI, Diego ODETTO, Rene LAKY, Ignacio ZAPARDIEL, Vít WEINBERGER, Klára BENEŠOVÁ, Martina BORČINOVÁ, Fernando CARDENAS, Emelie WALLIN, Luigi Pedone ANCHORA, Huseyin AKILLI, Nadeem R ABU-RUSTUM, Salim Abraham BARQUET-MUÑOZ, Veronika JAVŮRKOVÁ, Daniela FISCHEROVÁ and Luc R C W van LONKHUIJZEN. Post-recurrence survival in patients with cervical cancer. \textit{Gynecologic Oncology}. San Diego: Elsevier, 2022, vol.~164, No~2, p.~362-369. ISSN~0090-8258. Available from: https://dx.doi.org/10.1016/j.ygyno.2021.12.018.

Detailed Information on Publication Record